Alpha 2.0
Login Register
» Authors » Patrick K Owiafe

Patrick K Owiafe

Explore the profile of Patrick K Owiafe including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 313
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Science
Top 10 Co-Authors
Roger H Brookes
Philip C Hill
Richard A Adegbola
Abdulrahman S Hammond
Martin O C Ota
Moses D Lugos
David J Jeffries
Helen McShane
Simon A Donkor
Simon Donkor
Published In
Vaccine
Clin Infect Dis
PLoS One
Am J Respir Crit Care Med
Lancet Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants
Odutola A, Ota M, Antonio M, Ogundare E, Saidu Y, Owiafe P, et al.
Vaccine . 2019 Apr; 37(19):2586-2599. PMID: 30975570
Background: Two conserved pneumococcal proteins, pneumolysin toxoid (dPly) and pneumococcal histidine triad protein D (PhtD), combined with 10 polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV)...
2.
Infection in Close Childhood Contacts of Adults with Pulmonary Tuberculosis is Increased by Secondhand Exposure to Tobacco
Adetifa I, Kendall L, Donkor S, Lugos M, Hammond A, Owiafe P, et al.
Am J Trop Med Hyg . 2017 Jul; 97(2):429-432. PMID: 28722570
Tobacco use is a major risk factor for tuberculosis (TB). Secondhand smoke (SHS) is also a risk factor for TB and to a lesser extent, infection without disease. We investigated...
3.
Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study
Odutola A, Ota M, Antonio M, Ogundare E, Saidu Y, Foster-Nyarko E, et al.
Vaccine . 2017 Apr; 35(19):2531-2542. PMID: 28389097
Background: Conserved pneumococcal proteins are potential candidates for inclusion in vaccines against pneumococcal diseases. In the first part of a two-part study, an investigational vaccine (PHiD-CV/dPly/PhtD-30) containing 10 pneumococcal serotype-specific...
4.
Broad adaptive immune responses to M. tuberculosis antigens precede TST conversion in tuberculosis exposed household contacts in a TB-endemic setting
Buchwald U, Adetifa I, Bottomley C, Owiafe P, Donkor S, Bojang A, et al.
PLoS One . 2014 Dec; 9(12):e116268. PMID: 25549338
Background: The identification of Mycobacterium-tuberculosis (Mtb) infected individuals remains a challenge due to an insufficient understanding of immune responses detected with the current diagnostic tests for latent tuberculosis i.e. the...
5.
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial
Idoko O, Owolabi O, Owiafe P, Moris P, Odutola A, Bollaerts A, et al.
Tuberculosis (Edinb) . 2014 Oct; 94(6):564-78. PMID: 25305000
Unlabelled: We evaluated the candidate tuberculosis vaccine M72/AS01 in Bacille-Calmette-Guérin (BCG)-vaccinated infants after or concomitantly with Expanded-Programme-on-Immunization (EPI) vaccines. Methods: In a Phase-II study in The Gambia (NCT01098474), 2 cohorts...
6.
Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial
Adetifa I, Ota M, Jeffries D, Lugos M, Hammond A, Battersby N, et al.
Am J Respir Crit Care Med . 2012 Dec; 187(4):439-45. PMID: 23220919
Rationale: Biomarkers that can be used to evaluate new interventions against latent tuberculosis infection (LTBI) and predict reactivation TB disease are urgently required. Objectives: To evaluate ESAT-6 and CFP-10 (EC)...
7.
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants
Ota M, Odutola A, Owiafe P, Donkor S, Owolabi O, Brittain N, et al.
Sci Transl Med . 2011 Jun; 3(88):88ra56. PMID: 21697532
New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as...
8.
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa
Brookes R, Hill P, Owiafe P, Ibanga H, Jeffries D, Donkor S, et al.
PLoS One . 2008 Aug; 3(8):e2921. PMID: 18698342
Background: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and...
9.
The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo
Ota M, Brookes R, Hill P, Owiafe P, Ibanga H, Donkor S, et al.
Vaccine . 2007 Nov; 25(52):8861-7. PMID: 18023944
Understanding the immunogenicity of BCG in a population where it has failed will facilitate the design of new TB vaccines. We assessed the immunogenicity of M. bovis BCG over 12...
10.
ESAT-6 and CFP-10 can be combined to reduce the cost of testing for Mycobacterium tuberculosis infection, but CFP-10 responses associate with active disease
Fox A, Jeffries D, Hill P, Hammond A, Lugos M, Jackson-Sillah D, et al.
Trans R Soc Trop Med Hyg . 2007 Apr; 101(7):691-8. PMID: 17434194
Commercial tests measuring IFN-gamma responses to ESAT-6 and CFP-10 are available for diagnosing Mycobacterium tuberculosis infection. Measures that minimize cost and complexity will facilitate their application in less-developed countries. We...